Literature DB >> 19690522

Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients.

Gabriele Capurso1, Massimo Falconi, Francesco Panzuto, Maria Rinzivillo, Letizia Boninsegna, Rossella Bettini, Vito Corleto, Piero Borgia, Paolo Pederzoli, Aldo Scarpa, Gianfranco Delle Fave.   

Abstract

OBJECTIVES: Pancreatic endocrine tumors (PETs) are heterogeneous tumors with increasing prevalence. Little is known about the molecular pathogenesis and risk factors for the occurrence of sporadic PETs. The aim of this study was to identify the risk factors associated with the occurrence of sporadic PETs.
METHODS: A case-control study comprising 162 sporadic PETs and 648 controls was undertaken. Subjects were interviewed using a specific questionnaire on demographics and potential risk factors, including smoking, alcohol, height, weight, medical history, and family history of cancer. A multiple hierarchical logistic regression analysis was performed with a stepwise variable- selection procedure.
RESULTS: A first-degree family history of any cancer was a significant risk factor (odds ratio (OR) 2.2; 95% confidence interval (CI): 1.5-3.2). Among the different cancer sites, first-degree family history of pancreatic adenocarcinoma was more frequent in PETs than in controls (4.3 vs. 1.2%; P=0.01). A high alcohol intake (OR 4.8; 95% CI: 2.4-9.5), history of chronic pancreatitis (CP) (OR 8.6; 95% CI: 1.4-51), and recent-onset diabetes (OR 40.1; 95% CI: 4.8-328.9) were all independent risk factors. The history of diabetes was also associated with metastatic disease at the time of diagnosis.
CONCLUSIONS: This case-control study identified family history of any cancer (and to a less extent of pancreatic adenocarcinoma), CP, high alcohol intake, and recent-onset diabetes as risk factors for PET, thus suggesting a possible partial overlap with risk factors for exocrine pancreatic carcinogenesis.

Entities:  

Mesh:

Year:  2009        PMID: 19690522     DOI: 10.1038/ajg.2009.466

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

1.  Evidence-based clinical practice guidelines for chronic pancreatitis 2015.

Authors:  Tetsuhide Ito; Hiroshi Ishiguro; Hirotaka Ohara; Terumi Kamisawa; Junichi Sakagami; Naohiro Sata; Yoshifumi Takeyama; Morihisa Hirota; Hiroyuki Miyakawa; Hisato Igarashi; Lingaku Lee; Takashi Fujiyama; Masayuki Hijioka; Keijiro Ueda; Yuichi Tachibana; Yoshio Sogame; Hiroaki Yasuda; Ryusuke Kato; Keisho Kataoka; Keiko Shiratori; Masanori Sugiyama; Kazuichi Okazaki; Shigeyuki Kawa; Yusuke Tando; Yoshikazu Kinoshita; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-01-04       Impact factor: 7.527

2.  Impact of CT-based diagnostic imaging on management and outcome of nonfunctioning pancreatic tumors.

Authors:  Katja Maschuw; Volker Fendrich; Peter Langer; C Volland; Annette Ramaswamy; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2011-02-12       Impact factor: 3.445

3.  Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus.

Authors:  Sahityasri Thapi; Kiwoon Baeg; Michelle K Kim; Emily J Gallagher
Journal:  Pancreas       Date:  2021-10-01       Impact factor: 3.243

4.  Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective.

Authors:  Giovanna Muscogiuri; Barbara Altieri; Manuela Albertelli; Andrea Dotto; Roberta Modica; Luigi Barrea; Giuseppe Fanciulli; Tiziana Feola; Roberto Baldelli; Rosaria Maddalena Ruggeri; Marco Gallo; Valentina Guarnotta; Pasqualino Malandrino; Erika Messina; Mary Anna Venneri; Elisa Giannetta; Diego Ferone; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2020-05-28       Impact factor: 3.633

5.  Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals.

Authors:  Gabriele Capurso; Marianna Signoretti; Roberto Valente; Urban Arnelo; Matthias Lohr; Jan-Werner Poley; Gianfranco Delle Fave; Marco Del Chiaro
Journal:  World J Gastrointest Endosc       Date:  2015-07-25

6.  Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.

Authors:  T Feola; G Puliani; F Sesti; R Modica; R Centello; R Minotta; G Cannavale; S Di Meglio; V Di Vito; R Lauretta; M Appetecchia; A Colao; A Lenzi; A M Isidori; A Faggiano; E Giannetta
Journal:  J Endocrinol Invest       Date:  2022-01-18       Impact factor: 4.256

7.  Clinical characteristics and prognosis of primary pancreatic carcinoid tumors: A report of 13 cases from a single institution.

Authors:  Feng-Hua Liu; Chong Wang; Ya-Ling Xing; Jiang-Hua Wu; Yong Tang
Journal:  Oncol Lett       Date:  2014-12-08       Impact factor: 2.967

8.  Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors.

Authors:  Daniele Campa; Gabriele Capurso; Manuela Pastore; Renata Talar-Wojnarowska; Anna Caterina Milanetto; Luca Landoni; Evaristo Maiello; Rita T Lawlor; Ewa Malecka-Panas; Niccola Funel; Maria Gazouli; Antonio De Bonis; Harald Klüter; Maria Rinzivillo; Gianfranco Delle Fave; Thilo Hackert; Stefano Landi; Peter Bugert; Franco Bambi; Livia Archibugi; Aldo Scarpa; Verena Katzke; Christos Dervenis; Valbona Liço; Sara Furlanello; Oliver Strobel; Francesca Tavano; Daniela Basso; Rudolf Kaaks; Claudio Pasquali; Manuel Gentiluomo; Cosmeri Rizzato; Federico Canzian
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

9.  Association between ABO blood types and sporadic pancreatic neuroendocrine tumors in the Chinese Han population.

Authors:  Qiwen Ben; Jun Liu; Weiyi Wang; Fang Guo; Weiyan Yao; Jie Zhong; Yaozong Yuan
Journal:  Oncotarget       Date:  2017-06-21

10.  Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case-control study.

Authors:  Yael N Kusne; Heidi E Kosiorek; Matthew R Buras; Patricia M Verona; Kyle E Coppola; Kelley A Rone; Curtiss B Cook; Nina J Karlin
Journal:  Future Sci OA       Date:  2021-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.